Bettina Hentschel
Overview
Explore the profile of Bettina Hentschel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2388
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meuret S, Lemke S, Hentschel B, Fuchs M
Laryngorhinootologie
. 2024 Jun;
103(12):855-863.
PMID: 38843817
Objective: Teachers are subject to exceptionally high vocal stress throughout their lives and have an increased prevalence of voice disorders. The aim of this study was to evaluate the long-term...
2.
Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M, et al.
Acta Neuropathol
. 2024 Jan;
147(1):11.
PMID: 38183430
Prognostic factors and standards of care for astrocytoma, isocitrate dehydrogenase (IDH)-mutant, CNS WHO grade 4, remain poorly defined. Here we sought to explore disease characteristics, prognostic markers, and outcome in...
3.
Pertz M, Schlomer S, Seidel C, Hentschel B, Loffler M, Schackert G, et al.
J Neurooncol
. 2023 Aug;
164(2):353-366.
PMID: 37648934
Purpose: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients' neurocognition and quality of life. The present prospective multicenter study aimed...
4.
Bredel M, Espinosa L, Kim H, Scholtens D, McElroy J, Rajbhandari R, et al.
Cell Rep Med
. 2023 Jun;
4(6):101082.
PMID: 37343523
Genetic alterations help predict the clinical behavior of diffuse gliomas, but some variability remains uncorrelated. Here, we demonstrate that haploinsufficient deletions of chromatin-bound tumor suppressor NFKB inhibitor alpha (NFKBIA) display...
5.
Schlomer S, Felsberg J, Pertz M, Hentschel B, Loffler M, Schackert G, et al.
J Neurooncol
. 2022 Jul;
159(1):65-79.
PMID: 35796933
Purpose: Cognitive functioning represents an essential determinant of quality of life. Since significant advances in neuro-oncological treatment have led to prolonged survival it is important to reliably identify possible treatment-related...
6.
Gramatzki D, Felsberg J, Hentschel B, Bahr O, Westphal M, Schackert G, et al.
Neurooncol Pract
. 2021 Jul;
8(4):475-484.
PMID: 34277025
Background: The incidence of spinal cord gliomas, particularly in adults is low, and the role of chemotherapy has remained unclear. Methods: We performed a multicenter, retrospective study of 21 patients...
7.
Willscher E, Hopp L, Kreuz M, Schmidt M, Hakobyan S, Arakelyan A, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34206856
Molecular mechanisms of lower-grade (II-III) diffuse gliomas (LGG) are still poorly understood, mainly because of their heterogeneity. They split into astrocytoma- (IDH-A) and oligodendroglioma-like (IDH-O) tumors both carrying mutations(s) at...
8.
Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, et al.
Eur J Cancer
. 2021 Feb;
147:84-94.
PMID: 33631540
Aim Of The Study: Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O-methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent...
9.
Leo C, Hentschel B, Szucs T, Leo C
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32069837
Breast cancer is the most common cancer in women worldwide and the solid tumor type for which the highest number of drugs have been approved to date. This study examines...
10.
Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, et al.
J Cancer Res Clin Oncol
. 2019 Nov;
146(3):659-670.
PMID: 31754832
Background: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here, we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be...